Pharmacologic targeting of immune checkpoints like CD73 has substantial therapeutic potential in cancer treatment, but in addition to a (re-)activation of the anti-tumoral immune response, ICIs can also trigger a specific class of toxicities, irAEs, which include ICI pneumonitis (Guberina et al., 2023). This evidence concerns the gene NT5E and cancer.